“…CeOx has been cleared by the United States Food and Drug Administration for monitoring regional cerebral oxygen saturation [4], and cerebral deoxygenation (rSO 2 below 55%) has been shown to correlate with a variety of adverse systemic complications and multi-organ failure, for example, renal failure, overall well-being, prolonged ventilation, cortical dysfunction, cerebral hypoxia, and low cardiac output syndromes. Many studies [1,7,12,16] showed that CeOx with NIRS correlated with CPP estimation, the Glasgow Outcome Score Scale, and mortality in patients with severe TBI, and NIRS has the capability to provide an early warning of cerebral ischemia and infarction. These impacts of continuous monitoring showed the above correlations between regional cerebral saturation and systemic outcomes, and most of the intraoperative measures taken to optimize cerebral rSO 2 and oxygen delivery potentially affect systemic perfusion (e.g., alterations in PaCO 2 , cardiac output, arterial blood pressure, etc.).…”